Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC)

NCT00942825 is registered in ClinicalTrials.gov with CanBas Co. Ltd. as lead sponsor.

NCT NCT00942825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00942825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC)
Lead sponsor
CanBas Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
July 31, 2013
Enrollment
195 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-squamous non small cell lung cancer